Clinical Trials: Page 2
-
Courtesy of Edwards Lifesciences
Edwards pushes back on Medtronic’s head-to-head TAVR trial
Edwards Lifesciences and Wall Street analysts questioned the results of Medtronic’s women-focused study, claiming the data are inconsistent with real-world evidence.
By Susan Kelly • April 15, 2024 -
Courtesy of Exact Sciences
Exact Sciences’ cancer blood test achieves 51% sensitivity in prospective trial
Sensitivity for the multi-cancer early detection test rose to almost 64% in the six cancers with the shortest five-year survival rate.
By Nick Paul Taylor • April 9, 2024 -
Permission granted by Medtronic
Medtronic beats Edwards on valve dysfunction in TAVR study
In a head-to-head clinical trial, Medtronic linked its device to a lower rate of valve dysfunction than Edwards’ rival product in a subpopulation of patients.
By Nick Paul Taylor • April 8, 2024 -
Dmitry Belyaev via Getty Images
Freenome’s colorectal cancer blood test data underwhelm analysts
Cowen analysts said Freenome’s results are good news for competitors Exact Sciences and Guardant Health.
By Nick Paul Taylor • April 5, 2024 -
Courtesy of Exact Sciences
Exact Sciences, Mayo Clinic share early data on esophageal cancer test
Designed as an alternative to endoscopy, the cancer screening test uses a sponge collection device that's paired with an algorithm.
By Elise Reuter • March 29, 2024 -
Courtesy of Business Wire
Guardant posts data for colon cancer blood test amid push from rivals
The NEJM paper presents data from a study of more than 10,000 people Guardant ran to support authorization of its Shield DNA test.
By Nick Paul Taylor • March 18, 2024 -
Permission granted by Becton Dickinson
BD starts trial of vascular covered stent in peripheral arterial disease
Peripheral vascular disease is one of six key platforms BD is targeting for growth.
By Nick Paul Taylor • March 5, 2024 -
Mario Tama via Getty Images
J&J unveils Varipulse data at AF Symposium
The results compare favorably to data from Boston Scientific and Medtronic, although analysts noted that J&J enrolled younger patients.
By Nick Paul Taylor • Feb. 6, 2024 -
Courtesy of Medtronic
Medtronic’s closed-loop neuromodulation device cuts overstimulation in trial
Most participants reported a significant reduction in overstimulation compared to open-loop spinal cord stimulation.
By Nick Paul Taylor • Jan. 22, 2024 -
Courtesy of Abbott
Abbott starts study of PFA device in humans, targets 2024 US trial
RBC analysts predict Volt could launch in the U.S. as early as 2026.
By Nick Paul Taylor • Jan. 19, 2024 -
Sara Silbiger via Getty Images
FDA drafts guidance outlining real-world evidence for medical device submissions
By issuing the new guidance, the agency is meeting the requirements of a year-end spending bill.
By Elise Reuter • Dec. 19, 2023 -
Mohammed Haneefa Nizamudeen via Getty Images
Freenome starts 20,000-subject study of lung cancer blood test
The privately held company claims its test could offer an alternative to CT imaging, which exposes people to radiation.
By Nick Paul Taylor • Dec. 14, 2023 -
Photo illustration: Shaun Lucas/Industry Dive; CRISPR Therapeutics; Gregor Fischer/DPA/Newscom
Deep Dive‘No tolerance for failure’: An oral history of the first CRISPR medicine
A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. and U.K. This is the story of how it came to be.
By Ned Pagliarulo , Shaun Lucas • Dec. 13, 2023 -
Permission granted by Empatica
Empatica aims to develop seizure-forecasting algorithm based on wearable data
The company plans a study using its wrist-worn device to capture real-world data that could help understand and predict seizures for people with epilepsy.
By Nick Paul Taylor • Dec. 1, 2023 -
Christopher Furlong via Getty Images
AstraZeneca creates digital health unit, with big-name partnerships already in place
Called Evinova, the unit will operate as a separate business within AstraZeneca, which sees digital health solutions as a market primed for growth.
By Jacob Bell • Nov. 20, 2023 -
Courtesy of Abbott
Abbott study links aspirin-free regimen to better outcomes in heart pump patients
An accompanying editorial said the “data provide an opportunity to immediately improve the outcomes of patients implanted with contemporary LVADs.”
By Nick Paul Taylor • Nov. 15, 2023 -
Permission granted by Boston Scientific
Large registry study upholds safety findings for Boston Scientific’s Farapulse device
The results, presented at the American Heart Association Scientific Sessions, showed a low rate of adverse events for the pulsed-field ablation treatment.
By Elise Reuter • Nov. 14, 2023 -
Win McNamee/Getty Images via Getty Images
Biden initiative aims to accelerate women’s health research
AdvaMed endorsed the White House effort, stressing the need for equitable development and funding of new technologies.
By Susan Kelly • Nov. 14, 2023 -
Douglas Cliff via Getty Images
Wegovy study details revive debate over GLP-1 impact on devices
The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.
By Susan Kelly • Nov. 13, 2023 -
Courtesy of Johnson & Johnson
J&J links radiofrequency catheter to improved quality of life in atrial fibrillation study
Scores on a quality-of-life scale improved and use of antiarrhythmic drugs fell after people underwent treatment with the device.
By Nick Paul Taylor • Nov. 6, 2023 -
Permission granted by Penumbra
Penumbra touts benefits of vacuum thrombectomy for PE in late-breaking data
An interim analysis of Penumbra’s Indigo aspiration system met its primary safety and efficacy criteria, according to data shared at the Vascular Interventional Advances Conference.
By Elise Reuter • Nov. 3, 2023 -
Courtesy of Edwards Lifesciences
Edwards posts early look at tricuspid device, stoking Abbott rivalry ahead of FDA panel
Nearly 94% of patients had their condition improve to mild or no tricuspid regurgitation six months after treatment, according to the study.
By Nick Paul Taylor • Oct. 27, 2023 -
Courtesy of Abbott
Abbott’s resorbable scaffold improves outcomes in below-the-knee artery disease, study finds
The device maker plans to submit the Esprit BTK data to the Food and Drug Administration for review.
By Nick Paul Taylor • Oct. 26, 2023 -
Permission granted by Boston Scientific
Boston Scientific study results support coronary drug-coated balloon in US
The results, shared at TCT 2023, found the company’s drug-coated balloon performed better than an uncoated balloon in procedures to reopen blocked arteries.
By Elise Reuter • Oct. 25, 2023 -
magicmine via Getty Images
Edwards, Medtronic post low-risk TAVR data, allaying fears of market disruption
The late-breaking results, shared at TCT 2023, will have little impact on clinical practice or market share, J.P. Morgan and Stifel analysts predicted.
By Nick Paul Taylor • Oct. 25, 2023
Previous
